June 1, 2021
Zoetis Inc., the world’s leading animal health company, announced it has acquired the assets to Owl Manor’s range of devices for use in regenerative medicine therapies in equine and canine patients, which includes Pro-Stride® APS, Restigen® PRP, CenTrate® BMA and related products. Zoetis will be immediately incorporating this portfolio into the Zoetis Equine family of horse care products.
Grovet has been a proud channel partner of Owl Manor Veterinary since 2016 with exclusive rights for Europe, Middle East and South Africa. We are pleased to announce our partnership with Zoetis, and that our role in providing and supplying this portfolio of products will remain the same.
At Grovet, we look forward continuing to broaden the foothold in our markets with the Pro-Stride
